ArticleKorean circulation journal2026
Validation of the Asian-Dual Antiplatelet Therapy Score.
Article in Korean circulation journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Another Score in the Flood, or a Needed Step Toward East Asian Precision?Korean circulation journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAn individualized approach is recommended for prescribing dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). Asian-DAPT (ADAPT) scores were developed to assess both ischemic and bleeding risks in Asian populations. This study aimed to validate the ADAPT scores for predicting ischemic and bleeding events in patients receiving DAPT.
methodsPatients from the Multicenter Registry of KOrean PCI foR Endpoint Analysis registry were analyzed. The ADAPT scores, comprising the ischemic-ADAPT (I-ADAPT), bleeding-ADAPT (B-ADAPT), and Net-ADAPT scores, were calculated using clinical and angiographic parameters. Co-primary endpoints included ischemic outcomes (cardiovascular death, myocardial infarction, and stent thrombosis) and bleeding outcomes (major and minor bleeding).
resultsA total of 4,657 patients were included in analysis. The mean age was 63.8±11.1 years, and 72.3% were male. During a median follow-up of 368 days, ischemic outcomes occurred in 0.9% (43 patients), and bleeding outcomes in 0.9% (44 patients). The I-ADAPT and B-ADAPT scores had significant predictive values for ischemic outcomes (C-statistic=0.672; 95% confidence interval [CI], 0.585-0.758; p<0.001) and bleeding outcomes (C-statistic=0.715; 95% CI, 0.642-0.789; p<0.001), respectively. Regarding the Net-ADAPT score, patients with a score >0 were at a 1.7-fold higher risk of ischemic events, while those with a score of <0 had a 1.3-fold higher risk of bleeding events.
conclusionsThe ADAPT scores were validated for predicting ischemic and bleeding risks in patients receiving DAPT. This scoring system can aid in evaluating both ischemic and bleeding risks for East Asians, who exhibit unique risk profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.